Medical Use
Lonsurf is a fixed-dose combination medication that includes Trifluridine, a nucleoside metabolic inhibitor, and Tipiracil, a thymidine phosphorylase inhibitor. It is prescribed for adult patients with the following conditions:
- -Metastatic colorectal cancer: Lonsurf can be used alone or in combination with bevacizumab for patients who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as well as anti-VEGF biological therapy. For those with RAS wild-type cancer, it is also used following anti-EGFR therapy.
- -Metastatic gastric or gastroesophageal junction adenocarcinoma: This medication is an option for patients who have received at least two prior lines of chemotherapy, including a fluoropyrimidine, a platinum agent, and either a taxane or irinotecan. It is also used in patients who have received HER2/neu-targeted therapy, if applicable.
Recommended Dosage: The recommended dosage of Lonsurf, whether used alone or with bevacizumab, is 35 mg/m² (based on the trifluridine component) taken orally twice daily with food. The maximum dose per administration is 80 mg. This regimen should be followed on Days 1-5 and Days 8-12 of each 28-day cycle. Treatment continues until disease progression or unacceptable side effects occur. Dosages should be rounded to the nearest 5 mg
Warning & Precautions
Lonsurf tablets can lead to severe bone marrow suppression, resulting in neutropenia, anemia, and thrombocytopenia. It’s crucial to monitor blood counts before and during treatment. If severe hematologic toxicity occurs, dose adjustments or discontinuation may be necessary.
Trifluridine and Tipiracil can harm a fetus if administered to pregnant women. Women of reproductive potential should use effective contraception during treatment and for at least six months after the final dose.
Breastfeeding is not recommended during treatment with Lonsurf and for one day after the last dose, as the drug can be excreted in breast milk and may harm a breastfeeding infant. Patients should either discontinue breastfeeding or stop the drug, depending on its importance to the mother.
Hepatic Impairment: Exercise caution when administering Lonsurf (15 mg trifluridine/6.14 mg tipiracil & 20 mg trifluridine/8.19 mg tipiracil) to patients with moderate to severe hepatic impairment. Due to limited data, dosage adjustments or close monitoring may be needed because of potential changes in drug metabolism and increased toxicity risk.
Renal Impairment: Use Lonsurf cautiously in patients with moderate to severe renal impairment. Dosage adjustments may be required, and renal function should be closely monitored during treatment, as impaired renal function can lead to increased drug exposure and toxicity.
Documentation Availability
Documents required to import LONSURF to India?
LONSURF (Trifluridine and Tipiracil) tablet can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing LONSURF (a cancer treatment medication)from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for the trade name drug Lonsurf®?
The generic name for Lonsurf® is Trifluridine/Tipiracil.
What is the Manufacturer’s Name of Lonsurf®?
Lonsurf® is manufactured by Taiho Pharmaceutical Co., Ltd.
Is Lonsurf® approved by the FDA?
Yes, Lonsurf® received FDA approval on September 22, 2015.
What is the dosage and form of Lonsurf® supplied?
Lonsurf® is available in tablet form with two dosage strengths: 15 mg of trifluridine/6.14 mg of tipiracil and 20 mg of trifluridine/8.19 mg of tipiracil, intended for oral use.
What are the most common side effects of Lonsurf®?
The most common side effects when used alone include low blood counts, decreased appetite, fatigue, nausea, diarrhea, vomiting, abdominal pain, and fever. When combined with bevacizumab, common side effects include low blood counts, weakness, nausea, abnormal liver function tests, low sodium levels, diarrhea, stomach pain, and decreased appetite.
How much does Lonsurf® (Trifluridine and Tipiracil) cost in India?
Prices may vary due to market dynamics and regulatory changes. For the most accurate and up-to-date pricing, contact the Rx4u team.
What are the storage conditions of Lonsurf®?
Store Lonsurf® tablets at 20 to 25°C (68 to 77°F), with permissible excursions between 15 to 30°C (59°F to 86°F).
Is it safe to buy Lonsurf® online in India?
Yes, you can safely purchase Lonsurf® online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
